FLT3 and acute myeloid leukemia: This study randomized 717 patients either to midostaurin or a placebo, in addition to standard chemotherapy, and demonstrated that OS was better in the midostaurin arm than in the placebo arm, indicating that adding midostaurin to standard chemotherapy could improve survival in AML patients with a FLT3 mutation [18].